RITONAVIR | N020680 | ABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS DIV
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 4 | Active | Nova Scotia Health Authority | 44 | 2015-07-10 → 2025-10 | |
| — | APPROVED_FOR_MARKETING | Boehringer Ingelheim | — | 2004-12 | |
| Phase 1 | Completed | City of Hope Medical Center | 3 | 2017-09-07 → 2017-12-01 | |
| Phase 4 | Completed | University of California, San Diego | 65 | 2006-02-14 → 2012-06-13 | |
| Phase 1/2 | Completed | University of Ulm | 10 | 2016-11 → 2020-12 | |
| Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 52 | 2012-05 → 2013-05 | |
| Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 34 | — → 2004-05 | |
| Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 246 | — → 1999-01 | |
| Phase 3 | Completed | Hoffmann-La Roche | 375 | — | |
| Phase 2 | Completed | Tibotec Pharmaceuticals, Ireland | 27 | 2009-09 → 2011-02 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
15 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
No patent or exclusivity listings for this strength.